← Back to Search

Objective Pain Biomarkers for Pain

N/A
Waitlist Available
Led By Michael Froelich, MD
Research Sponsored by University of Alabama at Birmingham
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 20 minutes during the study session (once).
Awards & highlights

Study Summary

This trial is investigating whether changes in electrical brain activity can be used to measure pain.

Who is the study for?
This clinical trial is for adults over 18 years old who can understand the study procedures. It's not suitable for those with chronic pain, on medications like opioids or SSRIs that affect how we process pain, or with conditions like diabetic neuropathy or stroke that interfere with sensory processing.Check my eligibility
What is being tested?
The study is testing whether brain activity measured by standard EEG (electroencephalogram) and SSEP (somatosensory evoked potentials) can be used as objective markers to reflect a person's sensation of pain.See study design
What are the potential side effects?
Since this trial involves non-invasive brain activity measurements using EEG and SSEP, side effects are minimal but may include discomfort from wearing sensors or sitting still during the procedure.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~20 minutes during the study session (once).
This trial's timeline: 3 weeks for screening, Varies for treatment, and 20 minutes during the study session (once). for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Correlation of (electrical) pain intensity (X) and amplitude of SSEP (Y).

Trial Design

1Treatment groups
Experimental Treatment
Group I: Standard EEG or SSEPExperimental Treatment1 Intervention
the intensity of an experimental pain stimulus and perceived (self-rating, subjective) pain intensity.

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor
1,583 Previous Clinical Trials
2,280,034 Total Patients Enrolled
15 Trials studying Pain
7,083 Patients Enrolled for Pain
Michael Froelich, MDPrincipal InvestigatorUAB Department of Anesthesiology, Critical Care Division
2 Previous Clinical Trials
42 Total Patients Enrolled
1 Trials studying Pain
22 Patients Enrolled for Pain

Media Library

Standard EEG or SSEP Clinical Trial Eligibility Overview. Trial Name: NCT03495180 — N/A
Pain Research Study Groups: Standard EEG or SSEP
Pain Clinical Trial 2023: Standard EEG or SSEP Highlights & Side Effects. Trial Name: NCT03495180 — N/A
Standard EEG or SSEP 2023 Treatment Timeline for Medical Study. Trial Name: NCT03495180 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still vacancies available for participants in this trial?

"As per the information supplied on clinicaltrials.gov, this trial is currently not recruiting participants. It was initially published on May 22nd 2018 and last updated in March 4th 2022. Nevertheless, there are 344 other trials actively seeking enrolment at present."

Answered by AI

Who else is applying?

What state do they live in?
Alabama
How old are they?
18 - 65
What site did they apply to?
University of Alabama at Birmingham
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Quantitative SSEP and EEG as Objective Pain Biomarker
Michael Froelich 2018. "Quantitative SSEP and EEG as Objective Pain Biomarker". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03495180.
All > Pain Management > Pain
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top